RAPP (Rapport Therapeutics) Research & Development: $107.93 Mil (TTM As of Mar. 2026)


RAPP Rapport Therapeutics Inc RAPP
14 GF Score
Price $41.79
! 3 Warning Signs
View Full Analysis

What is Rapport Therapeutics Research & Development?

Rapport Therapeutics RAPP -0.60% 14 Research & Development is $107.93 Mil as of Mar. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Rapport Therapeutics's Research & Development for the three months ended in Mar. 2026 was $32.72 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $107.93 Mil.

Rapport Therapeutics  (NAS:RAPP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Rapport Therapeutics Research & Development Related Terms

Rapport Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Rapport Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics Research & Development Chart

Rapport Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
0.00 28.00 60.94 94.79

Rapport Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.57 22.68 22.28 30.26 32.72
RAPP
14GF Score
Rapport Therapeutics Inc RAPP
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapport Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $107.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $107.93 Mil mean?
Rapport Therapeutics (RAPP) has a Research & Development of $107.93 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Rapport Therapeutics and its competitors.
Is Rapport Therapeutics' Research & Development too high?
Rapport Therapeutics' current Research & Development is $107.93 Mil. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Research & Development compare to SION and TYRA?
Rapport Therapeutics' Research & Development of $107.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Rapport Therapeutics and its competitors. Rapport Therapeutics's current Research & Development is $107.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Research & Development of $107.93 Mil. The current Research & Development is $107.93 Mil. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Research & Development is $107.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapport Therapeutics Business Description

Address 99 High Street, Suite 2100, Boston, MA, USA, 02110
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score

Get the complete analysis for RAPP

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.79
Price